About taubiologic
TAU BIO LOGIC
PRECISION IMMUNOTHERAPY TARGETING ALZHEIMER'S DISEASE
WHO WE ARE
Commitment to Innovation
TAU BIO-LOGIC CORP. is a privately held biopharmaceutical company focused on the development of innovative high precision immunotherapies for the treatment of Alzheimer’s disease and related neurodegenerative conditions. The Company was established to accelerate the development of its lead compound, TBL-100 which has been shown in preclinical models to block the toxicity and propagation of tau pathology in nerve cells while avoiding the potential (inherent in other competitive molecules), to further disrupt cellular architecture. TAU BIO-LOGIC is investing in the optimization of TBL-100 to demonstrate safety, efficacy and dosing advantages versus competitors.while advancing the program toward the initiation of clinical trials in Alzheimer's patients. .
Our company is led by Daniel G. Chain, PhD, who is the inventor of the patents underlying TBL-100. Dr. Chain is a seasoned biotechnology executive and scientist entrepreneur dedicated to the development of therapeutics for the treatment of Alzheimer’s and other neurodegenerative diseases. For 20 years, he has established and managed companies in the neurodegeneration field, and his patented innovations helped enable the development of several monoclonal antibodies tested in late stage clinical trials for Alzheimer’s disease and related indications by global pharmaceutical companies. In addition, Dr. Chain spearheaded the development of a metal binding antioxidant clinical-stage compound currently under development for Friedreich’s Ataxia by Intellect Neurosciences, and a first-in-class clinical stage small molecule compound, itanapraced (CSP-1103), being developed for Parkinson’s disease and other indications by CereSpir Incorporated where Dr. Chain is also engaged. Dr. Chain trained as a biochemist and molecular neurobiologist having obtained his PhD from the Weizmann Institute of Sciences in Israel and subsequently trained as a researcher at Columbia College of Physicians and Surgeons in New York.
Alzheimer's Disease
Alzheimer’s disease (AD) is the most common cause of dementia and represents an enormous and growing global public health challenge. It is a uniformly fatal neurodegenerative disorder with no cure or substantially effective treatment. Alzheimer’s Disease International estimated that as of 2013, 44 million people had dementia worldwide, a figure which is expected to increase to 76 million people in 2030 and 136 million in 2050 because of the aging of societies globally (Alzheimer’s Disease International 2013). In the United States, the prevalence of AD in 2015 is estimated at 5 million people, a number which is anticipated to increase to 7 million in 2025 and to 14 million by 2050 (Alzheimer’s Association 2015). AD is a strongly age-associated disorder with onset mainly in later life; the great majority of individuals with the condition are over 65 years of age. Within the older adult population, the prevalence of AD increases dramatically from the sixth through the ninth decade; approximately one-third of individuals with AD currently are 85 years of age or older.
The estimated worldwide cost of dementia was a staggering $604 billion in 2010, with about 70% of the costs being incurred in Western Europe and North America (Alzheimer’s Disease International 2013). In view of the aforementioned epidemiologic trends, massive increases in costs associated with AD are anticipated globally in coming decades if no medical breakthroughs to prevent or cure the disease are developed.
AD is characterized clinically by progressive cognitive impairment, typically beginning as short-term memory impairment, but also notable for executive function deficits, sometimes early behavioral disturbances, and occasionally visuospatial impairment. Over time, the cognitive impairment worsens and affects activities of daily living (ADL). Initially, complex instrumental activities of daily living are impaired, and later, in dementia, basic activities of daily living are lost. The time course is lengthy, with the dementia stage alone often spanning more than a decade. Not only does the disease have a devastating impact on the quality of life for subjects and cause tremendous expense for society, but the protracted course of functional incapacity causes a terrible burden to caregivers, who are also typically elderly, and to other family members and loved ones.
Tau is the major constituent of neurofibrillary tangles, the hallmark pathological lesion that characterizes several diseases collectively referred to as tauopathies including AD which is also characterized by the common occurrence of plaque containing a different protein known as beta amyloid. It is increasingly evident that these two proteins act synergistically to promote pathology. Under disease conditions, tau protein is cleaved by enzymes to yield various fragments. TauC3 is a low abundance but highly noxious, secreted, C-terminally truncated tau fragment ending at aspartate 421. TauC3-induced neurotoxicity has been observed by many scientists with evidence that it may compromise neurons early in the disease and and be responsible for the spread of AD pathologythrough different regions of the brain.
TBL-100
TBL-100 is a very high affinity monoclonal antibody that specifically targets tauC3. Recently published results from cell culture experiments conducted by Harvard University, demonstrate that TBL-100 can block tau uptake and seeding of tau aggregation by brain tissue extracts from Alzheimer’s patients, indicating that it has the potential to prevent propagation of tau. Additionally,experiments conducted by UC Irvine, demonstrate that TBL-100 can engage its target intracellularly and reduce phosphorylation at select epitopes associated with pre-tangle tau pathology compatible with a possible intracellular locus of action of the antibody.
CONTACT US
Send Message
Name
Email*
Message
SEND
TAU BIO-LOGIC CORP.
41 Madison Avenue, 31st Floor, New York, NY 10010
(718) 406-1331
Copyright © 2017 TAU BIO-LOGIC CORP. - All Rights Reserved.
Powered by GoDaddy GoCentral Website Builder
Things that are equal to the same thing are also equal to one another (Transitive property of equality). If equals are added to equals, then the wholes are equal. If equals are subtracted from equals, then the remainders are equal. Things that coincide wi
